The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Cited by (1,019)

Items 201–300 of 1,019

1. Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms
   Adam Samuel Sperling, Veronica A. Guerra, James A. Kennedy, Yuanqing Yan, Joanne I. Hsu, Feng Wang, Andrew T. Nguyen, Peter Grant Miller, Marie Ellen McConkey, Vanessa A. Quevedo Barrios et al. · 2022 · Blood
2. The genomic and transcriptional landscape of primary central nervous system lymphoma
   Josefine Radke, Naveed Ishaque, Randi Koll, Zuguang Gu, Elisa Schumann, Lina Sieverling, Sebastian Uhrig, Daniel Hübschmann, Umut H. Toprak, Cristina López et al. · 2022 · Nature Communications
3. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes
   Matteo Giovanni Della Porta, Erica Travaglino, Emanuela Boveri, Maurilio Ponzoni, Luca Malcovati, Elli Papaemmanuil, Gian Matteo Rigolin, Cristiana Pascutto, Giorgio Alberto Croci, Umberto Gianelli et al. · 2014 · Leukemia
4. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey
   Claire N. Harrison, Steffen Koschmieder, Lynda M. Foltz, Paola Guglielmelli, Tina Flindt, Michael Koehler, Jonathan Mathias, Norio Komatsu, Robert N. Boothroyd, Amber Spierer et al. · 2017 · Annals of Hematology
5. Primary myelofibrosis: 2019 update on diagnosis, risk‐stratification and management
   Ayalew Tefferi · 2018 · American Journal of Hematology
6. OncoTree: A Cancer Classification System for Precision Oncology
   Ritika Kundra, Hongxin Zhang, Robert Sheridan, Sahussapont Joseph Sirintrapun, Avery Wang, Angelica Ochoa, Manda Wilson, Benjamin E Gross, Yichao Sun, Ramyasree Madupuri et al. · 2021 · JCO Clinical Cancer Informatics
7. Frontline treatment of acute myeloid leukemia in adults
   Gevorg Tamamyan, Tapan Mahendra Kadia, Farhad Ravandi, Gautam M. Borthakur, Jörge E. Cortes, Elias Joseph Jabbour, Naval Guastad Daver, Maro N. Ohanian, Hagop M. Kantarjian, Marina Y Konopleva · 2016 · Critical Reviews in Oncology/Hematology
8. Recent drug approvals for acute myeloid leukemia
   Catherine Lai, Kimberley Doucette, Kelly J. Norsworthy · 2019 · Journal of Hematology & Oncology
9. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia
   Andriana G. Kotini, Chan-Jung Chang, Arthur Chow, Han Yuan, Tzu‐Chieh Ho, Tiansu Wang, Shailee Vora, Alexander Solovyov, Chrystel Husser, Malgorzata Olszewska et al. · 2017 · Cell stem cell
10. Genetic predisposition to MDS: clinical features and clonal evolution
    Alyssa L. Kennedy, Akiko Shimamura · 2019 · Blood
11. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
    Ayalew Tefferi, Alessandro Maria Vannucchi, Tiziano Barbui · 2021 · Leukemia
12. A deep learning model (ALNet) for the diagnosis of acute leukaemia lineage using peripheral blood cell images
    Laura Boldú, Anna Merino, Andrea Acevedo, Ángel Molina, José Rodellar · 2021 · Computer Methods and Programs in Biomedicine
13. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
    Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Mikkael Aaron Sekeres, Michael Robert Savona, Yazan F. Madanat, María Díez‐Campelo, David Valcárcel, Thomas Illmer, Anna T Jonasova et al. · 2023 · The Lancet
14. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies
    Eric Padron, Guillermo Garcia‐Manero, Mrinal M. Patnaik, Raphaël Itzykson, Terra L. Lasho, Aziz Nazha, Raajit K. Rampal, Matias Eugenio Sanchez, Elias Joseph Jabbour, Najla H. Al Ali et al. · 2015 · Blood Cancer Journal
15. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Hendrik Bergsma, Kirsten van Lom, Marc H.G.P. Raaijmakers, Mark Konijnenberg, Boen L.R. Kam, Jaap J.M. Teunissen, Wouter W. de Herder, Eric P. Krenning, Dik J. Kwekkeboom · 2017 · Journal of Nuclear Medicine
16. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients
    Friederike Christen, Kaja Hoyer, Kenichi Yoshida, Hsin‐An Hou, Nils Waldhüter, Michael Heuser, Robert Kerrin Hills, Willy Chan, Raphael Hablesreiter, Olga Blau et al. · 2019 · Blood
17. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis
    Ryunosuke Saiki, Yukihide Momozawa, Yasuhito Nannya, Masahiro Marshall Nakagawa, Yotaro Ochi, Tetsuichi Yoshizato, Chikashi Terao, Yutaka Kuroda, Yuichi Shiraishi, Kenichi Chiba et al. · 2021 · Nature Medicine
18. Megakaryocyte and polyploidization
    Stefania Mazzi, Larissa Lordier, Najet Debili, Hana Raslová, William Vainchenker · 2017 · Experimental Hematology
19. Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience
    Antonio C. Wolff, Amanda L. Blackford, Kala Visvanathan, Hope S. Rugo, Beverly Moy, Lori J. Goldstein, Keith E Stockerl-Goldstein, Leigh A. Neumayer, Terry S. Langbaum, Richard L. Theriault et al. · 2014 · Journal of Clinical Oncology
20. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
    Peter Valent, Attilio Orazi, Michael Robert Savona, Mrinal M. Patnaik, Francesco Onida, Arjan A. van de Loosdrecht, Detlef Thomas Haase, Torsten Haferlach, Chiara Elena, Lisa Pleyer et al. · 2019 · Haematologica
21. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes
    Hamid Dolatshad, Andrea Pellagatti, Fabio Giuseppe Liberante, Miriam Llorian, Emmanouela Repapi, Violetta Steeples, S Roy, Laura Scifo, Richard Neil Armstrong, Jacqueline M. Shaw et al. · 2016 · Leukemia
22. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
    Farhad Ravandi, Rita Elias Assi, Naval Guastad Daver, Christopher Brent Benton, Tapan Mahendra Kadia, Philip A. Thompson, Gautam M. Borthakur, Yesid Alvarado, Elias Joseph Jabbour, Marina Y Konopleva et al. · 2019 · The Lancet Haematology
23. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management
    Mrinal M. Patnaik, Ayalew Tefferi · 2019 · American Journal of Hematology
24. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
    John O Mascarenhas, Heidi E. Kosiorek, Josef T. Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N. Harrison, Mary Frances McMullin, Alessandro M. Vannucchi, Joanne Ewing et al. · 2022 · Blood
25. Genomic subtyping and therapeutic targeting of acute erythroleukemia
    Iacobucci, Ilaria, Wen, Ji, Meggendorfer, Manja, Choi, John K., Shi, Lei, Pounds, Stanley B., Carmichael, Catherine L., Masih, Katherine E., Morris, Sarah M., Lindsley, R. Coleman et al. · 2019 · Nature Genetics
26. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements
    Ilaria Tanasi, Ibrahima Ba, Nicolas Sirvent, Thorsten Braun, Wendy Cuccuini, Paola Fabiola Ballerini, Nicolas Duployez, Aline Schmidt, Jérôme Tamburini, Sébastien Maury et al. · 2019 · Blood
27. Essential thrombocythemia treatment algorithm 2018
    Ayalew Tefferi, Alessandro Maria Vannucchi, Tiziano Barbui · 2018 · Blood Cancer Journal
28. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort
    Maximilian F. Stahl, Michelle DeVeaux, Théo de Witte, Judith Neukirchen, Mikkael Aaron Sekeres, Andrew Mark Brunner, Gail J. Roboz, David P. Steensma, Vijaya Raj Bhatt, Uwe Platzbecker et al. · 2018 · Blood Advances
29. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
    Montalban-Bravo, Guillermo, Kanagal-Shamanna, Rashmi, Benton, Christopher B., Class, Caleb A., Chien, Kelly S., Sasaki, Koji, Naqvi, Kiran, Alvarado, Yesid, Kadia, Tapan M., Ravandi, Farhad et al. · 2020 · Blood Advances
30. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
    Matteo Giovanni Della Porta, Heinz Tuechler, Luca Malcovati, Julie Schanz, Guillermo Francisco Sanz, Guillermo Garcia‐Manero, Francesc Gessé Solé, John M. Bennett, David Bowen, Pierre Fenaux et al. · 2015 · Leukemia
31. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia
    Daniel B. Lipka, Tania Witte, Réka Tóth, Jing Yang, Manuel Wiesenfarth, Peter Noellke, Alexandra Fischer, David Brocks, Zuguang Gu, Jeongbin Park et al. · 2017 · Nature Communications
32. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
    Heikki A Kuusanmäki, Olli Dufva, Markus J. V. Vähä-Koskela, Aino‐Maija Leppä, Jani Huuhtanen, Ida Vänttinen, Petra Johanna Nygren, Jay Klievink, Jonas Bouhlal, Petri Pölönen et al. · 2022 · Blood
33. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use
    Ulrike Bacher, Evgenii Shumilov, Johanna Flach, Naomi Azur Porret, Raphael Joncourt, Gertrud Wiedemann, Martin Fiedler, Urban Novak, Ursula Amstutz, Thomas Pabst · 2018 · Blood Cancer Journal
34. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
    Hartmut Döhner, Anna Dolnik, Lin Tang, John Francis Seymour, Mark David Minden, Richard Maury Stone, Teresa Bernal, Haifa Kathrin Al‐Ali, Valeria Santini, Paresh Vyas et al. · 2018 · Leukemia
35. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition
    Margarita M. Dzama, Marlene Steiner, Johanna Rausch, Daniel Sasca, Jonas Schönfeld, Kerstin Kunz, Martha C. Taubert, Gerard M. McGeehan, Chun-Wei David Chen, Annalisa Mupo et al. · 2020 · Blood
36. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved
    Rory Michael Shallis, Robert Peter Gale, Hillard Michael Lazarus, Kenneth B. Roberts, Mina L. Xu, Stuart Seropian, Steven D. Gore, Nikolai Alexandrovich Podoltsev · 2020 · Blood Reviews
37. Splicing factor gene mutations in hematologic malignancies
    Borja Sáez, Matthew J. Walter, Timothy Aaron Graubert · 2016 · Blood
38. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation
    Andrew Tucker Kuykendall, Savan Shah, Chetasi Talati, Najla E. Al Ali, Kendra Lynn Sweet, Eric Padron, David Andrew Sallman, Jeffrey E. Lancet, Alan F. List, Kenneth S. Zuckerman et al. · 2017 · Annals of Hematology
39. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
    Ayalew Tefferi, Maura Nicolosi, Mythri Mudireddy, Terra L. Lasho, Naseema Gangat, Kebede H. Begna, Curtis A. Hanson, Rhett P. Ketterling, Animesh Dev Pardanani · 2018 · Leukemia
40. MRD in AML: The Role of New Techniques
    Maria Teresa Voso, Tiziana Ottone, Serena Lavorgna, Adriano Venditti, Luca Maurillo, Francesco Lo‐Coco, Francesco Buccisano · 2019 · Frontiers in Oncology
41. The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia
    Dimitrios Papaioannou, Andreas Petri, Oliver M. Dovey, Sara Terreri, Eric Wang, Frances A. Collins, Lauren A. Woodward, Allison E. Walker, Deedra Nicolet, Felice Pepe et al. · 2019 · Nature Communications
42. Hereditary thrombocytopenias: a growing list of disorders
    Patrizia Noris, Alessandro Pecci · 2017 · Hematology
43. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
    Erika Morsia, Kristen Beth McCullough, Maansi Joshi, Joselle Cook, Hassan B. Alkhateeb, Aref Al‐Kali, Kebede H. Begna, Michelle Ann Elliott, William J. Hogan, Mark Robert Litzow et al. · 2020 · American Journal of Hematology
44. Vascular endothelial cell expression of JAK2 V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression
    Alexandre Guy, Virginie Gourdou‐Latyszenok, Nicolas Le Lay, Claire R. Peghaire, Badr Kilani, Juliana Vieira Dias, Cécile Duplàa, Marie‐Ange Renault, Cécile V. Denis, Jean‐Luc Villeval et al. · 2018 · Haematologica
45. MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
    Mohamad Jawhar, Juliana Schwaab, Iván Álvarez‐Twöse, Khalid Shoumariyeh, Nicole Naumann, Johannes Lübke, Cecelia Perkins, Javier I. Muñoz‐González, Manja Meggendorfer, Vanessa Elaine Kennedy et al. · 2019 · Journal of Clinical Oncology
46. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
    Margherita Maffioli, Barbara Mora, Somedeb Ball, Alessandra Iurlo, Elena Maria Elli, Maria Chiara Finazzi, Nicola Polverelli, Elisa Rumi, Marianna Caramella, Maria Cristina Carraro et al. · 2022 · Blood Advances
47. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management
    Pardanani, Animesh · 2023 · American Journal of Hematology
48. FLT3–ITD and its current role in acute myeloid leukaemia
    Francisco Alejandro Lagunas‐Rangel, Venice Chávez‐Valencia · 2017 · Medical Oncology
49. Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
    Rita Elias Assi, Hagop M. Kantarjian, Tapan Mahendra Kadia, Naveen Pemmaraju, Elias Joseph Jabbour, Nitin Jain, Naval Guastad Daver, Zeev E. Estrov, Taisuke Uehara, Takashi Owa et al. · 2018 · Cancer
50. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears
    Jan‐Niklas Eckardt, Jan Moritz Middeke, Sebastian Riechert, Tim Schmittmann, Anas Shekh Sulaiman, Michael Krämer, Katja Sockel, Frank Kroschinsky, Ulrich S. Schuler, Johannes Schetelig et al. · 2021 · Leukemia
51. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis
    Virginia Hernández–Gea, Andrea De Gottardi, Frank W.G. Leebeek, Pierre‐Emmanuel Rautou, Riad Salem, Juan Carlos García‐Pagán · 2019 · Journal of Hepatology
52. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML
    Andrew H. Wei, Ing Soo Tiong · 2017 · Blood
53. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances
    Tiziano Barbui, J. Thiele, Heinz Gisslinger, Guido Finazzi, Alessandro Maria Vannucchi, Ayalew Tefferi · 2016 · Blood Reviews
54. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
    Dhifaf Sarhan, Ludwig Brandt, Martin Felices, Karolin Guldevall, Todd R. Lenvik, Peter Hinderlie, Julie Curtsinger, Erica Dahl Warlick, Stephen R. Spellman, Bruce R. Blazar et al. · 2018 · Blood Advances
55. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
    Sibylle Cocciardi, Anna Dolnik, Silke Kapp‐Schwoerer, Frank G. Rücker, Susanne Lux, Tamara J. Blätte, Sabrina Skambraks, Jan Krönke, Florian Heinrich Heidel, Tina M. Schnoeder et al. · 2019 · Nature Communications
56. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia
    Wenbin Xiao, Alexander C. L. Chan, Michael R. Waarts, Tanmay Mishra, Ying Liu, Sheng F. Cai, JinJuan Yao, Qi Gao, Robert L. Bowman, Richard P. Koche et al. · 2020 · Blood
57. Evans’ Syndrome: From Diagnosis to Treatment
    Sylvain Audia, Natacha Grienay, Morgane Mounier, Marc Michel, Bernard Bonnotte · 2020 · Journal of Clinical Medicine
58. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
    He, Yonghan, Khan, Sajid, Huo, Zhiguang, Lv, Dongwen, Zhang, Xuan, Liu, Xingui, Yuan, Yaxia, Hromas, Robert, Xu, Mingjiang, Zheng, Guangrong et al. · 2020 · Journal of Hematology & Oncology
59. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
    Frank G. Rücker, Mridul Agrawal, Andrea Corbacioglu, Daniela Weber, Silke Kapp‐Schwoerer, Verena I. Gaidzik, Nikolaus Jahn, Thomas A. Schroeder, Mohammed Amen Wattad, Michael Lübbert et al. · 2019 · Blood
60. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
    Sayer Al-harbi, Mahmoud Deeb Aljurf, Mohamad Mohty, Fahad I. Almohareb, Syed Osman Ali Ahmed · 2020 · Blood Advances
61. Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome
    Nicola Guzzi, Sowndarya Muthukumar, Maciej Cieśla, Gabriele Todisco, Phuong Cao Thi Ngoc, Magdalena Madej, Roberto Munita, Serena Fazio, Simon Ekström, Teresa Mortera Blanco et al. · 2022 · Nature Cell Biology
62. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
    Elisabetta Sauta, Marie Robin, Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, Lin‐Pierre Zhao, Juan Carlos Caballero Berrocal, Claudia Sala, Giulia Maggioni, Massimo Bernardi et al. · 2023 · Journal of Clinical Oncology
63. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes
    Koichi Takahashi, Feng Wang, Kiyomi Morita, Yuanqing Yan, Peter C. Hu, Pei Zhao, Abdallah Abou Zhar, Chang Wu, Curtis E. Gumbs, Latasha Little et al. · 2018 · Nature Communications
64. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
    Brian J. Ball, Christopher A. Famulare, Eytan M. Stein, Martin S. Tallman, Andriy Derkach, Mikhail Roshal, Saar I. Gill, Benjamin M. Manning, Jamie Lynn Koprivnikar, James K. McCloskey et al. · 2020 · Blood Advances
65. Acute myeloid leukemia: 2021 update on risk‐stratification and management
    Elihu H. Estey · 2020 · American Journal of Hematology
66. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
    A Toma, Olivier Kosmider, Sylvie Chevret, Jacques Delaunay, Aspasia Stamatoullas, Christian Rosé, Odile Beyne‐Rauzy, A. Baños, Agnès Guerci‐Bresler, Stefan Wickenhauser et al. · 2015 · Leukemia
67. Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL
    Elisabeth M. Paietta, Kathryn G. Roberts, Victoria Wang, Zhaohui Gu, Georgina A. N. Buck, Deqing Pei, Cheng Cheng, Ross L. Levine, Omar Ibrahim Abdel-Wahab, Zhongshan Cheng et al. · 2021 · Blood
68. Pathophysiology of Acute Myeloid Leukemia
    Franziska Wachter, Yana Pikman · 2024 · Acta Haematologica
69. The molecular genetics of sideroblastic anemia
    Ducamp, Sarah, Fleming, Mark D. · 2019 · Blood
70. How I treat myelodysplastic syndromes of childhood
    Franco Locatelli, Brigitte Strahm · 2018 · Blood
71. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study
    Kasiani C. Myers, Elissa Furutani, Edie A. Weller, Bradford J. Siegele, Ashley Galvin, Valérie Arsenault, Blanche P. Alter, Farid Boulad, Carlos Bueso-Ramos, Lauri M. Burroughs et al. · 2019 · The Lancet Haematology
72. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria
    Lova Sun, Daria V. Babushok · 2020 · Blood
73. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial
    Silke Kapp‐Schwoerer, Daniela Weber, Andrea Corbacioglu, Verena I. Gaidzik, Peter Paschka, Jan Krönke, Frauke Theis, Frank G. Rücker, Maria‐Veronica Teleanu, Ekaterina Panina et al. · 2020 · Blood
74. Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults
    Raphaël Itzykson, Pierre Fenaux, David Bowen, Nicholas C.P. Cross, Jörge E. Cortes, Théo de Witte, Ulrich Germing, Francesco Onida, Eric Padron, Uwe Platzbecker et al. · 2018 · HemaSphere
75. Molecular pathogenesis of the myeloproliferative neoplasms
    Graeme Greenfield, Mary Frances McMullin, Ken Mills · 2021 · Journal of Hematology & Oncology
76. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
    Elias Joseph Jabbour, Nicholas James Short, Nitin Jain, Fadi Haddad, Mary Alma Welch, Farhad Ravandi, Hagop M. Kantarjian · 2023 · Journal of Hematology & Oncology
77. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management
    William E. Shomali, Jason R. Gotlib · 2024 · American Journal of Hematology
78. Scalable Prediction of Acute Myeloid Leukemia Using High-Dimensional Machine Learning and Blood Transcriptomics
    Warnat-Herresthal, Stefanie, Perrakis, Konstantinos, Taschler, Bernd, Becker, Matthias, Baßler, Kevin, Beyer, Marc, Günther, Patrick, Schulte-Schrepping, Jonas, Seep, Lea, Klee, Kathrin et al. · 2020 · iScience
79. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations
    Broesby‐Olsen, S., Vestergaard, H., Mortz, C. G., Jensen, B., Havelund, T., Hermann, A. P., Siebenhaar, F., Møller, M. B., Kristensen, T. K., Bindslev‐Jensen, C. et al. · 2018 · Allergy
80. Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia
    Mary‐Elizabeth M. Percival, Catherine Lai, Elihu H. Estey, Christopher Simon Hourigan · 2017 · Blood Reviews
81. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts
    Linus Angenendt, Christoph Röllig, Pau Montesinos, David Martínez‐Cuadrón, Eva Barragán, Raimundo García, Carmen Botella, Pilar Martı́nez, Farhad Ravandi, Tapan Mahendra Kadia et al. · 2019 · Journal of Clinical Oncology
82. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
    Massimo Vincenzo Martino, Caterina Alati, Filippo Antonio Canale, Gerardo Musuraca, Giovanni Martinelli, Claudio Cerchione · 2021 · International Journal of Molecular Sciences
83. CEBPA -bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group
    Katherine Tarlock, Adam J. Lamble, Yi‐Cheng Wang, Robert B. Gerbing, Rhonda E. Ries, Michael R. Loken, Lisa Eidenschink Brodersen, Laura M. Pardo, Amanda R. Leonti, Jenny L. Smith et al. · 2021 · Blood
84. Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology
    Daniel A. Arber, Michael J. Borowitz, Melissa H. Cessna, Joan E. Etzell, Kathryn K. Foucar, Robert Paul Hasserjian, J. Douglas Rizzo, Karl S. Theil, Sa A. Wang, Anthony T. Smith et al. · 2017 · Archives of Pathology & Laboratory Medicine
85. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
    Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Natasha Szuber, Kebede H. Begna, Mrinal M. Patnaik, Naseema Gangat, Animesh Dev Pardanani et al. · 2018 · Blood Advances
86. Clinical diagnostics and treatment strategies for Philadelphia chromosome–like acute lymphoblastic leukemia
    Richard C. Harvey, Sarah Kathleen Tasian · 2020 · Blood Advances
87. Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
    Robert Paul Hasserjian, David P. Steensma, Timothy Aaron Graubert, Benjamin L. Ebert · 2020 · Blood
88. Inherited Platelet Disorders: An Updated Overview
    Verónica Palma‐Barqueros, Nuria Revilla, Ana Sánchez, Ana Zamora‐Cánovas, Agustín Rodríguez‐Alén, Ana Marín‐Quilez, José Ramón González‐Porras, Vicente Vicente, Marı́a Luisa Lozano, José María Bastida et al. · 2021 · International Journal of Molecular Sciences
89. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies
    Sanjib Das, Sk. Abdul Amin, Tarun Jha · 2021 · European Journal of Medicinal Chemistry
90. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
    Paola Guglielmelli, Giuseppe Gaetano Loscocco, Carmela Mannarelli, Elena Rossi, Francesco Mannelli, Francesco Ramundo, Giacomo Coltro, Silvia Betti, Chiara Maccari, Sara Ceglie et al. · 2021 · Blood Cancer Journal
91. Clinical presentation and characteristics of lymphoma in the head and neck region
    Katharina Storck, Markus Brandstetter, Ulrich Bernd Keller, Andreas Knopf · 2019 · Head & Face Medicine
92. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy
    Guillermo Montalban Bravo, Rashmi Kanagal‐Shamanna, Koji Sasaki, Keyur Pravinchandra Patel, Irene Gañán‐Gómez, Elias Joseph Jabbour, Tapan Mahendra Kadia, Farhad Ravandi, Courtney Denton Dinardo, Gautham Borthakur et al. · 2019 · Blood Advances
93. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
    Boddu, Prajwal, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Ravandi, Farhad, Verstovsek, Srdan, Jabbour, Elias, Borthakur, Gautam, Konopleva, Marina, Bhalla, Kapil N., Daver, Naval et al. · 2017 · Blood Advances
94. Harnessing the immune system in acute myeloid leukaemia
    Rebecca J. Austin, Mark John Smyth, Steven Lane · 2016 · Critical Reviews in Oncology/Hematology
95. Genomic determinants of chronic myelomonocytic leukemia
    Bhumika J. Patel, Bartlomiej P. Przychodzen, Swapna Thota, Tomas Radivoyevitch, Valeria Visconte, Teodora Kuzmanovic, Michael J. Clemente, Cassandra M. Hirsch, Aaron R. Morawski, Roy Souaid et al. · 2017 · Leukemia
96. Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
    Christina Rautenberg, Ulrich Germing, Rainer R. Haas, Guido Kobbe, Thomas A. Schroeder · 2019 · International Journal of Molecular Sciences
97. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
    Ana Rio‐Machín, Tom Vulliamy, Nele Hug, Amanda J. Walne, Kiran Tawana, Shirleny Romualdo Cardoso, Alicia Ellison, Nikolas Pontikos, Jun Wang, Hemanth Tummala et al. · 2020 · Nature Communications
98. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival
    Ghaith F. Abu-Zeinah, Spencer Krichevsky, Tatiana Cruz, Gabriela Hoberman, Diana Alexandra Jaber, Niamh Savage, Claudia Sosner, Ellen Kelly Ritchie, Joseph Michael Scandura, Richard T. Silver · 2021 · Leukemia
99. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers
    Mohamad Jawhar, Juliana Schwaab, Nicole Naumann, Hans‐Peter Horny, Karl Sotlar, Torsten Haferlach, Georgia Metzgeroth, Alice Charlotte Fabarius, Peter Valent, Wolf‐Karsten Hofmann et al. · 2017 · Blood
100. How I treat chronic myelomonocytic leukemia
     Éric Solary, Raphaël Itzykson · 2017 · Blood